Review

rabbit monoclonal anti epha2 (R&D Systems)

Name: rabbit monoclonal anti epha2
Brand: R&D Systems
Rating: 93 (13 reviews)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems rabbit monoclonal anti epha2

A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) shows high <t>EphA2</t> expression in castration resistant, commercially available human PCa cell lines. B) Immunoblot characterization of select human PCa cell lines show increased EphA2 expression and S897 phosphorylation in mCRPC derived cell lines. C) EphA2 expression in representative human prostate cancer cell lines. D) Lysate of human prostate cancer tissues reveal increased expression of EphA2 in bone metastasis samples. Lysates were prepared from micro-dissected human prostate cancer tissues under the Rapid Autopsy Program at the Univ. Mich. PCa SPORE.

Rabbit Monoclonal Anti Epha2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 13 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal anti epha2/product/R&D Systems
Average 93 stars, based on 13 article reviews

rabbit monoclonal anti epha2 - by Bioz Stars, 2026-02

93/100 stars

Images

1) Product Images from "Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment"

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

Journal: bioRxiv

doi: 10.1101/2024.09.25.615079

Figure Legend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) shows high EphA2 expression in castration resistant, commercially available human PCa cell lines. B) Immunoblot characterization of select human PCa cell lines show increased EphA2 expression and S897 phosphorylation in mCRPC derived cell lines. C) EphA2 expression in representative human prostate cancer cell lines. D) Lysate of human prostate cancer tissues reveal increased expression of EphA2 in bone metastasis samples. Lysates were prepared from micro-dissected human prostate cancer tissues under the Rapid Autopsy Program at the Univ. Mich. PCa SPORE.

Techniques Used: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot, Derivative Assay

A) Diagram depicting the serial propagation of TRAMP-C1 cells in syngeneic mice to select for cells with increased tumorigenic capacity. B) The in vivo selection of cells resulted in accelerated tumor growth and reduced latency. C) Immunoblot analyses of the in vivo selected (IV1) and the parental TRAMP-C1 cells using the indicated antibodies. D,E,F,G,H,I,J) Quantification of relative band intensity (n = 4). All bands normalized to tubulin, except for pY588 and pS897 which are normalized to total EphA2 expression. K) Immunoblot of TRAMP-C1 parental and IV1 cells after stimulation with Ephrin-A1-Fc ligand for the indicated times. L,M) MPC3 and MycCaP cells were propagated in syngeneic C57Bl/6 and FVB mice, respectively. Lysates of the parental and the in vivo selected cells (IV1) were subject to immunoblot using the indicated antibodies.

Figure Legend Snippet: A) Diagram depicting the serial propagation of TRAMP-C1 cells in syngeneic mice to select for cells with increased tumorigenic capacity. B) The in vivo selection of cells resulted in accelerated tumor growth and reduced latency. C) Immunoblot analyses of the in vivo selected (IV1) and the parental TRAMP-C1 cells using the indicated antibodies. D,E,F,G,H,I,J) Quantification of relative band intensity (n = 4). All bands normalized to tubulin, except for pY588 and pS897 which are normalized to total EphA2 expression. K) Immunoblot of TRAMP-C1 parental and IV1 cells after stimulation with Ephrin-A1-Fc ligand for the indicated times. L,M) MPC3 and MycCaP cells were propagated in syngeneic C57Bl/6 and FVB mice, respectively. Lysates of the parental and the in vivo selected cells (IV1) were subject to immunoblot using the indicated antibodies.

Techniques Used: In Vivo, Selection, Western Blot, Expressing

A) Immunohistochemical (IHC) analyses of tissue microarray (TMA) prepared from primary, lymph node metastatic (LN), and bone metastatic human PCa tissues from the Rapid Autopsy Program of the Pacific Northwest PCa SPORE spotted. B and C) The relative IHC staining strengths of EphA2 and pS897-EphA2 on TMA was scored using 0-3 scale (0, absent; 1, weak; 2, moderate; 3, strong) . Data consists of 27 bone metastatic samples, and 18 soft tissue samples including 10 lymph node, 5 liver, and 3 lung metastatic samples. Comparisons were made using an unpaired t-test (B, p = 0.0003 C, p < 0.0001) D) mRNA expression analysis of human PCa metastatic biopsies revealed that bone metastases have the highest EphA2 expression compared to other sites of disease dissemination. Data from 208 samples from the SU2C/PCF Dream Team. mRNA Expression z-scores relative to all samples (log FPKM Capture) accessed via cBioportal. E) Kaplan-Meier curve of patients with bone metastases according to the levels of EphA2 expression.

Figure Legend Snippet: A) Immunohistochemical (IHC) analyses of tissue microarray (TMA) prepared from primary, lymph node metastatic (LN), and bone metastatic human PCa tissues from the Rapid Autopsy Program of the Pacific Northwest PCa SPORE spotted. B and C) The relative IHC staining strengths of EphA2 and pS897-EphA2 on TMA was scored using 0-3 scale (0, absent; 1, weak; 2, moderate; 3, strong) . Data consists of 27 bone metastatic samples, and 18 soft tissue samples including 10 lymph node, 5 liver, and 3 lung metastatic samples. Comparisons were made using an unpaired t-test (B, p = 0.0003 C, p < 0.0001) D) mRNA expression analysis of human PCa metastatic biopsies revealed that bone metastases have the highest EphA2 expression compared to other sites of disease dissemination. Data from 208 samples from the SU2C/PCF Dream Team. mRNA Expression z-scores relative to all samples (log FPKM Capture) accessed via cBioportal. E) Kaplan-Meier curve of patients with bone metastases according to the levels of EphA2 expression.

Techniques Used: Immunohistochemical staining, Microarray, Immunohistochemistry, Expressing

A) Immunoblot analysis of PC3 cells transduced with lentivirus to express WT-EphA2 or S897A-EphA2. Empty vector-transduced cells were used as control. Cells were starved for 24 hours in serum-free medium and stimulated with either FBS alone or FBS togethr with ephrin-A1-Fc. B) PC3 cells overexpressing WT-EphA2 or S897A-EphA2 mutant were xenografted subcutaneously into nude mice (n = 10 per group). Vector alone cells were used as control. Comparison between WT-EphA2 and S897A-EphA2 made with an unpaired t-test at day 46 post-injection (p = 0.0402).

Figure Legend Snippet: A) Immunoblot analysis of PC3 cells transduced with lentivirus to express WT-EphA2 or S897A-EphA2. Empty vector-transduced cells were used as control. Cells were starved for 24 hours in serum-free medium and stimulated with either FBS alone or FBS togethr with ephrin-A1-Fc. B) PC3 cells overexpressing WT-EphA2 or S897A-EphA2 mutant were xenografted subcutaneously into nude mice (n = 10 per group). Vector alone cells were used as control. Comparison between WT-EphA2 and S897A-EphA2 made with an unpaired t-test at day 46 post-injection (p = 0.0402).

Techniques Used: Western Blot, Transduction, Plasmid Preparation, Control, Mutagenesis, Comparison, Injection

Figure Legend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) showing low Efna1-5 gene expression in commercially available castration resistant and androgen sensitive human PCa cell lines. B) Immunoblot characterization of select PCa cell lines reveals simultaneous high EphA2 expression and low EphrinA1 expression in metastatic castration resistant cells compared with androgen sensitive cells. C ) Quantitative analysis of data in (B). D) Kaplan-Meier survival curve from the MSK dataset ( Cancer Cell 2010 ). Samples were aggregated into the top 25 percent EFNA1 expressing ( EFNA1 High), and lower 75 percent EFNA1 expressing ( EFNA1 Low). Data were accessed via cBioportal.

Techniques Used: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot

A) Lysates of PC-3 cells transduced by lentiviral vector expressing EFNA1 (EA1) or empty control vector were subject to immunoblot with the indicated antibodies. B,C) Quantification of pY588 marking canonical signaling and pS897 marking noncanonical signaling by EphA2, relative to total EphA2 expression. D) Vec. and EA1-expressing PC-3 cells were stimulated with recombinant exogenous EA1-Fc ligand in vitro for the indicated times, and lysates were subject to immunoblot with the indicated antibodies. E) PY99, a monoclonal antibody that recognizes most pY motifs, was used to probe overall pY profiles using lysates from Vec. and EA1-expressing PC-3 cells stimulated with EA1-Fc. N-cadherin and pY416-Src were also probed. F) PC-3 cells expressing EA1 exhibit reduced cell growth in an in vitro cell proliferation assay. G) Vec. control and EA1-expressing cells were implanted subcutaneously into nude mice. Paired t-test to be used to monitor (p = 0.0319). G) Bioluminescence imaging of mice four and six weeks after intratibial injection of PC3-vec. or PC-3-EA1 expressing cells tagged with luciferase. H) X-ray imaging of mice 6 weeks post intratibial injection of PC3-Vec and PC3-EA1 cells.

Figure Legend Snippet: A) Lysates of PC-3 cells transduced by lentiviral vector expressing EFNA1 (EA1) or empty control vector were subject to immunoblot with the indicated antibodies. B,C) Quantification of pY588 marking canonical signaling and pS897 marking noncanonical signaling by EphA2, relative to total EphA2 expression. D) Vec. and EA1-expressing PC-3 cells were stimulated with recombinant exogenous EA1-Fc ligand in vitro for the indicated times, and lysates were subject to immunoblot with the indicated antibodies. E) PY99, a monoclonal antibody that recognizes most pY motifs, was used to probe overall pY profiles using lysates from Vec. and EA1-expressing PC-3 cells stimulated with EA1-Fc. N-cadherin and pY416-Src were also probed. F) PC-3 cells expressing EA1 exhibit reduced cell growth in an in vitro cell proliferation assay. G) Vec. control and EA1-expressing cells were implanted subcutaneously into nude mice. Paired t-test to be used to monitor (p = 0.0319). G) Bioluminescence imaging of mice four and six weeks after intratibial injection of PC3-vec. or PC-3-EA1 expressing cells tagged with luciferase. H) X-ray imaging of mice 6 weeks post intratibial injection of PC3-Vec and PC3-EA1 cells.

Techniques Used: Plasmid Preparation, Expressing, Control, Western Blot, Recombinant, In Vitro, Proliferation Assay, Imaging, Injection, Luciferase

Image Search Results

CCLE and TCGA database of mRNA expression of EphA2. A) EphA2 expression in cell lines in CCLE. B) EphA2 mRNA expression in different types of tumors in TCGA. C) Comparison of mRNA expression of EphA2 in different normal tissues and corresponding tumors. D) Expression of different EPH receptors in pancreatic tumors. PAAD = pancreatic cancer; BLCA = Bladder cancer; READ = Rectal cancer; LUSC = Lung squamous cell carcinoma; THCA = Thyroid cancer; KIRP = Kidney papillary cell carcinoma; LUAD = Lung adenocarcinoma; KIRC = Kidney clear cell carcinoma; CHOL = Bile duct cancer; SKCM = melanoma; LIHC = Liver cancer; KICH = Kidney chromophobe; BRCA = Breast cancer; PRAD = Prostate cancer; DLBC = Large-B-cell lymphoma; LAML = Acute myeloid leukemia.

Journal: Theranostics

Article Title: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

doi: 10.7150/thno.106948

Figure Lengend Snippet: CCLE and TCGA database of mRNA expression of EphA2. A) EphA2 expression in cell lines in CCLE. B) EphA2 mRNA expression in different types of tumors in TCGA. C) Comparison of mRNA expression of EphA2 in different normal tissues and corresponding tumors. D) Expression of different EPH receptors in pancreatic tumors. PAAD = pancreatic cancer; BLCA = Bladder cancer; READ = Rectal cancer; LUSC = Lung squamous cell carcinoma; THCA = Thyroid cancer; KIRP = Kidney papillary cell carcinoma; LUAD = Lung adenocarcinoma; KIRC = Kidney clear cell carcinoma; CHOL = Bile duct cancer; SKCM = melanoma; LIHC = Liver cancer; KICH = Kidney chromophobe; BRCA = Breast cancer; PRAD = Prostate cancer; DLBC = Large-B-cell lymphoma; LAML = Acute myeloid leukemia.

Article Snippet: Similarly mouse pancreatic cell lines were stained with FITC labeled anti-mouse EphA2 monoclonal antibody (SinoBiological Cat # 50586-R301-F).

Techniques: Expressing, Comparison

Structure and in vitro characterization of AJ201. A) Structure of bicyclic peptide AJ201 having NOTA as bifunctional chelator for 68 Ga-labeling. In the structure, black color represents binding moiety, parakeet color represents the linker and red color represents the radiometal B) Surface plasmon resonance (SPR) analysis showing affinity of AJ201 for EphA2 using recombinant human (solid) and mouse (dashed) EphA2 proteins.

Journal: Theranostics

Article Title: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

doi: 10.7150/thno.106948

Figure Lengend Snippet: Structure and in vitro characterization of AJ201. A) Structure of bicyclic peptide AJ201 having NOTA as bifunctional chelator for 68 Ga-labeling. In the structure, black color represents binding moiety, parakeet color represents the linker and red color represents the radiometal B) Surface plasmon resonance (SPR) analysis showing affinity of AJ201 for EphA2 using recombinant human (solid) and mouse (dashed) EphA2 proteins.

Article Snippet: Similarly mouse pancreatic cell lines were stained with FITC labeled anti-mouse EphA2 monoclonal antibody (SinoBiological Cat # 50586-R301-F).

Techniques: In Vitro, Labeling, Binding Assay, SPR Assay, Recombinant

In vitro specificity of [ 68 Ga]AJ201 for EphA2 in human pancreatic cancer cells. A) Quantification of EphA2-mRNA using RT-PCR. B) Flow cytometry analysis of EphA2 receptor expression on cell surface. C) A representative plot of EphA2 receptor density in PDAC cells measured by quantibrite assay. D) [ 68 Ga]AJ201 binding (percent incubated activity, %IA) to different cells. Cells were incubated with 1 µCi [ 68 Ga]AJ201 at 4 °C for 1 h. [ 68 Ga]AJ201 uptake is EphA2 expression dependent, and co-incubation with 2 μM of non-radioactive AJ201 (0.2 nmol, blocking dose) significantly reduced radiotracer uptake confirming EphA2 specificity. E) In vitro uptake of [ 68 Ga]AJ201 over 60 min in Panc1 cells at 4 ˚C and 37 ˚C. F) Correlation of [ 68 Ga]AJ201 uptake with surface EphA2 receptor density. Data in panels A , D , E and F are presented as mean ± SD (n = 3-4). Significance was calculated using multiple unpaired t test in D ; ns, P ≥ 0.05; *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001. Simple linear regression and Pearson coefficient were used in F . All in vitro experiments were performed three times and representatives are shown.

Journal: Theranostics

Article Title: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

doi: 10.7150/thno.106948

Figure Lengend Snippet: In vitro specificity of [ 68 Ga]AJ201 for EphA2 in human pancreatic cancer cells. A) Quantification of EphA2-mRNA using RT-PCR. B) Flow cytometry analysis of EphA2 receptor expression on cell surface. C) A representative plot of EphA2 receptor density in PDAC cells measured by quantibrite assay. D) [ 68 Ga]AJ201 binding (percent incubated activity, %IA) to different cells. Cells were incubated with 1 µCi [ 68 Ga]AJ201 at 4 °C for 1 h. [ 68 Ga]AJ201 uptake is EphA2 expression dependent, and co-incubation with 2 μM of non-radioactive AJ201 (0.2 nmol, blocking dose) significantly reduced radiotracer uptake confirming EphA2 specificity. E) In vitro uptake of [ 68 Ga]AJ201 over 60 min in Panc1 cells at 4 ˚C and 37 ˚C. F) Correlation of [ 68 Ga]AJ201 uptake with surface EphA2 receptor density. Data in panels A , D , E and F are presented as mean ± SD (n = 3-4). Significance was calculated using multiple unpaired t test in D ; ns, P ≥ 0.05; *, P ≤ 0.05; ***, P ≤ 0.001; ****, P ≤ 0.0001. Simple linear regression and Pearson coefficient were used in F . All in vitro experiments were performed three times and representatives are shown.

Article Snippet: Similarly mouse pancreatic cell lines were stained with FITC labeled anti-mouse EphA2 monoclonal antibody (SinoBiological Cat # 50586-R301-F).

Techniques: In Vitro, Reverse Transcription Polymerase Chain Reaction, Flow Cytometry, Expressing, Binding Assay, Incubation, Activity Assay, Blocking Assay

In vivo specificity of [ 68 Ga]AJ201 for EphA2 in NSG mice with PDAC tumor xenografts. A) Whole-body PET/CT images of different human PDAC xenografts at 60 min after the injection of radiotracer. Mice were injected with ~ 7.4 MBq (~200 µCi) [ 68 Ga]AJ201; K, kidney. Panc1 mouse image is reproduced from figure E. B) [ 68 Ga]AJ201 uptake quantification (%ID/g) in different PDAC tumors by ex vivo biodistribution at 60 min after injection. Left: %ID/g of different tumor xenografts, tumor-to-blood (middle) and tumor-to-muscle (right) ratios in each individual mice harboring respective xenografts. C) IHC staining for EphA2 expression in PDAC xenografts (digitally scanned at 40x).; data in figure B is shown as box and whisker plots (median ± IQR) showing all data points (n = 4-5).

Journal: Theranostics

Article Title: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

doi: 10.7150/thno.106948

Figure Lengend Snippet: In vivo specificity of [ 68 Ga]AJ201 for EphA2 in NSG mice with PDAC tumor xenografts. A) Whole-body PET/CT images of different human PDAC xenografts at 60 min after the injection of radiotracer. Mice were injected with ~ 7.4 MBq (~200 µCi) [ 68 Ga]AJ201; K, kidney. Panc1 mouse image is reproduced from figure E. B) [ 68 Ga]AJ201 uptake quantification (%ID/g) in different PDAC tumors by ex vivo biodistribution at 60 min after injection. Left: %ID/g of different tumor xenografts, tumor-to-blood (middle) and tumor-to-muscle (right) ratios in each individual mice harboring respective xenografts. C) IHC staining for EphA2 expression in PDAC xenografts (digitally scanned at 40x).; data in figure B is shown as box and whisker plots (median ± IQR) showing all data points (n = 4-5).

Article Snippet: Similarly mouse pancreatic cell lines were stained with FITC labeled anti-mouse EphA2 monoclonal antibody (SinoBiological Cat # 50586-R301-F).

Techniques: In Vivo, Positron Emission Tomography-Computed Tomography, Injection, Ex Vivo, Immunohistochemistry, Expressing, Whisker Assay

In vivo distribution of [ 68 Ga]AJ201 in Panc1-orthotopic tumor model. A) Coronal sections of the fused PET/MR images showing [ 68 Ga]AJ201 distribution. Primary tumor is indicated by red circle; K = Kidney, B = Bladder. B) Quantification of accumulated activity in tumor, muscle and pancreas of images shown in panel A (n = 4-5) C) tumor-to-muscle (T/M) and tumor-to-pancreas (T/P) ratios from the images shown in panel A (n = 4) D) EphA2 IHC of orthotopic Panc1 tumor and normal pancreas to validate the EphA2 expression. Panc1 orthotopic tumor model was generated by surgically implanting a 3-5 mm³ section of Panc1 tumor xenograft directly onto the pancreas. The implanted tumors were allowed to grow for 10 days, after which they were ready for imaging. At this stage, MRI measurements indicated that tumor sizes ranged from 10-50 mm 3 . data in figure B and C is shown as box and whisker plots (median ± IQR) showing all data points (n = 3-5).

Journal: Theranostics

Article Title: EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment

doi: 10.7150/thno.106948

Figure Lengend Snippet: In vivo distribution of [ 68 Ga]AJ201 in Panc1-orthotopic tumor model. A) Coronal sections of the fused PET/MR images showing [ 68 Ga]AJ201 distribution. Primary tumor is indicated by red circle; K = Kidney, B = Bladder. B) Quantification of accumulated activity in tumor, muscle and pancreas of images shown in panel A (n = 4-5) C) tumor-to-muscle (T/M) and tumor-to-pancreas (T/P) ratios from the images shown in panel A (n = 4) D) EphA2 IHC of orthotopic Panc1 tumor and normal pancreas to validate the EphA2 expression. Panc1 orthotopic tumor model was generated by surgically implanting a 3-5 mm³ section of Panc1 tumor xenograft directly onto the pancreas. The implanted tumors were allowed to grow for 10 days, after which they were ready for imaging. At this stage, MRI measurements indicated that tumor sizes ranged from 10-50 mm 3 . data in figure B and C is shown as box and whisker plots (median ± IQR) showing all data points (n = 3-5).

Article Snippet: Similarly mouse pancreatic cell lines were stained with FITC labeled anti-mouse EphA2 monoclonal antibody (SinoBiological Cat # 50586-R301-F).

Techniques: In Vivo, Positron Emission Tomography-Magnetic Resonance Imaging, Activity Assay, Expressing, Generated, Imaging, Whisker Assay

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) shows high EphA2 expression in castration resistant, commercially available human PCa cell lines. B) Immunoblot characterization of select human PCa cell lines show increased EphA2 expression and S897 phosphorylation in mCRPC derived cell lines. C) EphA2 expression in representative human prostate cancer cell lines. D) Lysate of human prostate cancer tissues reveal increased expression of EphA2 in bone metastasis samples. Lysates were prepared from micro-dissected human prostate cancer tissues under the Rapid Autopsy Program at the Univ. Mich. PCa SPORE.

Article Snippet: Other antibodies were purchased as follows: Rabbit monoclonal anti-GAPDH (Cell Signaling Technology #2118S), rabbit monoclonal anti-pS473-Akt (Cell Signaling Technology #4060), rabbit polyclonal anti-pErk1/pErk2 (Cell Signaling Technology #9101S), rabbit monoclonal anti-EphA2 (Cell Signaling Technology #6697S), rat monoclonal anti-EphA2-PE (R&D Systems FAB639P), rabbit monoclonal anti-AR (Abcam ab133273), rabbit polyclonal anti-pY772-EphA2 (Cell Signaling Technology #8244S), rabbit monoclonal anti-pY588-EphA2 (Cell Signaling Technology #12677S), mouse monoclonal anti-Tubulin (R&D Systems MAB9344) Goat anti-rabbit and goat anti-mouse secondary antibodies conjugated to horseradish peroxidase (HRP) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and from Biorad (#1706515, and #1706516 respectively).

Techniques: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot, Derivative Assay

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Diagram depicting the serial propagation of TRAMP-C1 cells in syngeneic mice to select for cells with increased tumorigenic capacity. B) The in vivo selection of cells resulted in accelerated tumor growth and reduced latency. C) Immunoblot analyses of the in vivo selected (IV1) and the parental TRAMP-C1 cells using the indicated antibodies. D,E,F,G,H,I,J) Quantification of relative band intensity (n = 4). All bands normalized to tubulin, except for pY588 and pS897 which are normalized to total EphA2 expression. K) Immunoblot of TRAMP-C1 parental and IV1 cells after stimulation with Ephrin-A1-Fc ligand for the indicated times. L,M) MPC3 and MycCaP cells were propagated in syngeneic C57Bl/6 and FVB mice, respectively. Lysates of the parental and the in vivo selected cells (IV1) were subject to immunoblot using the indicated antibodies.

Techniques: In Vivo, Selection, Western Blot, Expressing

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Immunohistochemical (IHC) analyses of tissue microarray (TMA) prepared from primary, lymph node metastatic (LN), and bone metastatic human PCa tissues from the Rapid Autopsy Program of the Pacific Northwest PCa SPORE spotted. B and C) The relative IHC staining strengths of EphA2 and pS897-EphA2 on TMA was scored using 0-3 scale (0, absent; 1, weak; 2, moderate; 3, strong) . Data consists of 27 bone metastatic samples, and 18 soft tissue samples including 10 lymph node, 5 liver, and 3 lung metastatic samples. Comparisons were made using an unpaired t-test (B, p = 0.0003 C, p < 0.0001) D) mRNA expression analysis of human PCa metastatic biopsies revealed that bone metastases have the highest EphA2 expression compared to other sites of disease dissemination. Data from 208 samples from the SU2C/PCF Dream Team. mRNA Expression z-scores relative to all samples (log FPKM Capture) accessed via cBioportal. E) Kaplan-Meier curve of patients with bone metastases according to the levels of EphA2 expression.

Techniques: Immunohistochemical staining, Microarray, Immunohistochemistry, Expressing

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Immunoblot analysis of PC3 cells transduced with lentivirus to express WT-EphA2 or S897A-EphA2. Empty vector-transduced cells were used as control. Cells were starved for 24 hours in serum-free medium and stimulated with either FBS alone or FBS togethr with ephrin-A1-Fc. B) PC3 cells overexpressing WT-EphA2 or S897A-EphA2 mutant were xenografted subcutaneously into nude mice (n = 10 per group). Vector alone cells were used as control. Comparison between WT-EphA2 and S897A-EphA2 made with an unpaired t-test at day 46 post-injection (p = 0.0402).

Techniques: Western Blot, Transduction, Plasmid Preparation, Control, Mutagenesis, Comparison, Injection

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) showing low Efna1-5 gene expression in commercially available castration resistant and androgen sensitive human PCa cell lines. B) Immunoblot characterization of select PCa cell lines reveals simultaneous high EphA2 expression and low EphrinA1 expression in metastatic castration resistant cells compared with androgen sensitive cells. C ) Quantitative analysis of data in (B). D) Kaplan-Meier survival curve from the MSK dataset ( Cancer Cell 2010 ). Samples were aggregated into the top 25 percent EFNA1 expressing ( EFNA1 High), and lower 75 percent EFNA1 expressing ( EFNA1 Low). Data were accessed via cBioportal.

Techniques: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Lysates of PC-3 cells transduced by lentiviral vector expressing EFNA1 (EA1) or empty control vector were subject to immunoblot with the indicated antibodies. B,C) Quantification of pY588 marking canonical signaling and pS897 marking noncanonical signaling by EphA2, relative to total EphA2 expression. D) Vec. and EA1-expressing PC-3 cells were stimulated with recombinant exogenous EA1-Fc ligand in vitro for the indicated times, and lysates were subject to immunoblot with the indicated antibodies. E) PY99, a monoclonal antibody that recognizes most pY motifs, was used to probe overall pY profiles using lysates from Vec. and EA1-expressing PC-3 cells stimulated with EA1-Fc. N-cadherin and pY416-Src were also probed. F) PC-3 cells expressing EA1 exhibit reduced cell growth in an in vitro cell proliferation assay. G) Vec. control and EA1-expressing cells were implanted subcutaneously into nude mice. Paired t-test to be used to monitor (p = 0.0319). G) Bioluminescence imaging of mice four and six weeks after intratibial injection of PC3-vec. or PC-3-EA1 expressing cells tagged with luciferase. H) X-ray imaging of mice 6 weeks post intratibial injection of PC3-Vec and PC3-EA1 cells.

Techniques: Plasmid Preparation, Expressing, Control, Western Blot, Recombinant, In Vitro, Proliferation Assay, Imaging, Injection, Luciferase

Figure 3. N. glabratus mnn10Δ mutants induce higher phosphorylation of OEC EphA2 compared to their respective wild-type parental strains. Western blotting for total and phosphorylated EphA2 (pEpha2). Human α-actin, loading control. Figure is representative of three independent experiments. OECs, oral epithelial cells, negative control. SC5314, C. albicans reference strain, positive control. WT, wild-type strain. mnn10Δ, null mutant strain.

Journal: Virulence

Article Title: Mannan is a context-dependent shield that modifies virulence in Nakaseomyces glabratus .

doi: 10.1080/21505594.2025.2491650

Figure Lengend Snippet: Figure 3. N. glabratus mnn10Δ mutants induce higher phosphorylation of OEC EphA2 compared to their respective wild-type parental strains. Western blotting for total and phosphorylated EphA2 (pEpha2). Human α-actin, loading control. Figure is representative of three independent experiments. OECs, oral epithelial cells, negative control. SC5314, C. albicans reference strain, positive control. WT, wild-type strain. mnn10Δ, null mutant strain.

Article Snippet: Antibodies for assessment of EphA2 phosphorylation Anti-EphA2 (D4A2) and anti-p-EphA2 (S897) rabbit monoclonal antibodies were purchased from Cell Signaling Technologies (CST Inc., MA, USA) (catalogue numbers 6997S and 6347S, respectively).

Techniques: Phospho-proteomics, Western Blot, Control, Negative Control, Positive Control, Mutagenesis

Validation of the radiation-induced expression of the targets chosen based on the proteomics data using Western blot (A-C) and immunofluorescence (D-F). (A) representatives examples of staining in Western blot; data from a single experiment with anti-EPHA2 and a single experiment with anti-IGF2R is shown. TUBA1A was used as the loading control; lane 1 corresponds to non-irradiated HCC-44 cells grown adherently, lane 2 to irradiated HCC-44 cells grown adherently, lane 3 to non-irradiated A549 cells grown adherently, lane 4 to irradiated A549 cells grown adherently, lane 5 to non-irradiated A549 cells grown as spheroids, lane 6 to irradiated A549 cells grown as spheroids. For better visualization, the contrast of image parts showing EPHA2 and IGF2R staining was reduced; the quantification shown in B and C was carried out using non-modified images. (B, C) Pooled Western blot staining data normalized first to loading control and then separately to the corresponding non-irradiated control (NT) in each independent experiment (N = 4). Each column represents average ± standard error of mean; the immunostained protein names are mentioned in the graph header and the cell lines and treatment conditions below the graph. Statistical significance of paired comparisons (t-test): * corresponds to P < 0.05; (*) corresponds to P < 0.1; ns, not significant. (D-E) Signal intensity established from the microscopy images following IF; the immunostained protein names are mentioned in the graph header and cell treatment conditions prior to lysis below the graph. Each point corresponds to one region of interest in one frame; thick black line shows median and whiskers show interquartile range; data from all independent experiments was pooled (N = 4). Statistical significance of paired comparisons (Mann-Whitney test): *** corresponds to P < 0.001; * corresponds to P < 0.05; ns, not significant.

Journal: bioRxiv

Article Title: Proteome changes associated with effect of high-dose single-fractionation radiation on lung adenocarcinoma cell lines

doi: 10.1101/2025.01.21.634048

Figure Lengend Snippet: Validation of the radiation-induced expression of the targets chosen based on the proteomics data using Western blot (A-C) and immunofluorescence (D-F). (A) representatives examples of staining in Western blot; data from a single experiment with anti-EPHA2 and a single experiment with anti-IGF2R is shown. TUBA1A was used as the loading control; lane 1 corresponds to non-irradiated HCC-44 cells grown adherently, lane 2 to irradiated HCC-44 cells grown adherently, lane 3 to non-irradiated A549 cells grown adherently, lane 4 to irradiated A549 cells grown adherently, lane 5 to non-irradiated A549 cells grown as spheroids, lane 6 to irradiated A549 cells grown as spheroids. For better visualization, the contrast of image parts showing EPHA2 and IGF2R staining was reduced; the quantification shown in B and C was carried out using non-modified images. (B, C) Pooled Western blot staining data normalized first to loading control and then separately to the corresponding non-irradiated control (NT) in each independent experiment (N = 4). Each column represents average ± standard error of mean; the immunostained protein names are mentioned in the graph header and the cell lines and treatment conditions below the graph. Statistical significance of paired comparisons (t-test): * corresponds to P < 0.05; (*) corresponds to P < 0.1; ns, not significant. (D-E) Signal intensity established from the microscopy images following IF; the immunostained protein names are mentioned in the graph header and cell treatment conditions prior to lysis below the graph. Each point corresponds to one region of interest in one frame; thick black line shows median and whiskers show interquartile range; data from all independent experiments was pooled (N = 4). Statistical significance of paired comparisons (Mann-Whitney test): *** corresponds to P < 0.001; * corresponds to P < 0.05; ns, not significant.

Article Snippet: The rabbit monoclonal antibody against human Ephrin Type-A Receptor 2 (anti-EPHA2, clone D4A2) was from Cell Signaling Technology (catalogue number #6997; Danvers, Massachusetts, USA); the rabbit monoclonal antibody against human Insulin-Like Growth Factor 2 Receptor (anti-IGF2R) was from Sigma-Aldrich (catalogue number HPA011332; Saint Louis, Missouri, USA); the mouse monoclonal antibody against Tubulin Alpha 1a (anti-TUBA1A, clone DM1A) was from Novus Biologicals (catalogue number NB100-690; Centennial, Colorado, USA).

Techniques: Expressing, Western Blot, Immunofluorescence, Staining, Control, Irradiation, Modification, Microscopy, Lysis, MANN-WHITNEY

Representative examples of EPHA2 staining in irradiated vs non-irradiated adherent fixed cells. Data from a single experiment is shown; the channels (nuclear stain DAPI, protein of interest, and TUBA1A) are listed above the images; the cell lines and treatment conditions are listed on the left (NT stands for not irradiated). Scale bar (top left): 50 μm.

Journal: bioRxiv

Article Title: Proteome changes associated with effect of high-dose single-fractionation radiation on lung adenocarcinoma cell lines

doi: 10.1101/2025.01.21.634048

Figure Lengend Snippet: Representative examples of EPHA2 staining in irradiated vs non-irradiated adherent fixed cells. Data from a single experiment is shown; the channels (nuclear stain DAPI, protein of interest, and TUBA1A) are listed above the images; the cell lines and treatment conditions are listed on the left (NT stands for not irradiated). Scale bar (top left): 50 μm.

Techniques: Staining, Irradiation

$Viability/proliferation assay in irradiated vs non-irradiated adherent cells in the presence vs absence of EPHA2 and CTSD inhibitors. (A, B) Dose-response curves. Pooled normalized viability/proliferation is shown (N = 3); the cell line is indicated above the graphs and the treatment conditions below the graphs. Each column represents average ± standard error of mean; the data points were fit to the biphasic equation. MAX corresponds to the non-treated cells in case of non-irradiated cell dose-response and to 10 Gy-treated cells in case of the irradiated cell dose response. (C) Summary of the potent phase fraction statistics obtained based on the curves shown in panels A and B. The cell lines are indicated in the bottom part of the graph; each column represents average ± standard deviation. Statistical significance of the paired comparisons (t-test): *** corresponds to P < 0.001; ** corresponds to P < 0.01; ns, not significant.$

Journal: bioRxiv

Article Title: Proteome changes associated with effect of high-dose single-fractionation radiation on lung adenocarcinoma cell lines

doi: 10.1101/2025.01.21.634048

Figure Lengend Snippet: Viability/proliferation assay in irradiated vs non-irradiated adherent cells in the presence vs absence of EPHA2 and CTSD inhibitors. (A, B) Dose-response curves. Pooled normalized viability/proliferation is shown (N = 3); the cell line is indicated above the graphs and the treatment conditions below the graphs. Each column represents average ± standard error of mean; the data points were fit to the biphasic equation. MAX corresponds to the non-treated cells in case of non-irradiated cell dose-response and to 10 Gy-treated cells in case of the irradiated cell dose response. (C) Summary of the potent phase fraction statistics obtained based on the curves shown in panels A and B. The cell lines are indicated in the bottom part of the graph; each column represents average ± standard deviation. Statistical significance of the paired comparisons (t-test): *** corresponds to P < 0.001; ** corresponds to P < 0.01; ns, not significant.

Techniques: Proliferation Assay, Irradiation, Standard Deviation

Spheroid formation assay in irradiated vs non-irradiated A549 cells in the presence vs absence of EPHA2 and CTSD inhibitors. (A-H) Representative examples of spheroids formed during 96 h post-seeding. Data from a single experiment is shown; the treatment conditions are listed in the top right corner of each panel (NT stands for not treated). Scale bar (top left): 400 μm. (I) Pooled normalized area of spheroids at 96 h post-seeding (N = 3); the treatment conditions are listed below the graphs. Each column represents average ± standard deviation. Statistical significance of the grouped comparisons (Kruskal-Wallis test): *** corresponds to P < 0.001; ** corresponds to P < 0.01; * corresponds to P < 0.05; only significant comparisons are shown; arrows indicate the treatments (non-treated A549 or irradiated A549) to which other treatments are compared. Statistical significance of paired comparisons (Mann-Whitney test, only carried out for pepstatin A treatment versus cells not treated with inhibitors): (***) corresponds to P < 0.001; (**) corresponds to P < 0.01; only significant comparisons are shown. Abbreviations: ALW, ALW-II-41-27; pepstatin, pepstatin A.

Journal: bioRxiv

Article Title: Proteome changes associated with effect of high-dose single-fractionation radiation on lung adenocarcinoma cell lines

doi: 10.1101/2025.01.21.634048

Figure Lengend Snippet: Spheroid formation assay in irradiated vs non-irradiated A549 cells in the presence vs absence of EPHA2 and CTSD inhibitors. (A-H) Representative examples of spheroids formed during 96 h post-seeding. Data from a single experiment is shown; the treatment conditions are listed in the top right corner of each panel (NT stands for not treated). Scale bar (top left): 400 μm. (I) Pooled normalized area of spheroids at 96 h post-seeding (N = 3); the treatment conditions are listed below the graphs. Each column represents average ± standard deviation. Statistical significance of the grouped comparisons (Kruskal-Wallis test): *** corresponds to P < 0.001; ** corresponds to P < 0.01; * corresponds to P < 0.05; only significant comparisons are shown; arrows indicate the treatments (non-treated A549 or irradiated A549) to which other treatments are compared. Statistical significance of paired comparisons (Mann-Whitney test, only carried out for pepstatin A treatment versus cells not treated with inhibitors): (***) corresponds to P < 0.001; (**) corresponds to P < 0.01; only significant comparisons are shown. Abbreviations: ALW, ALW-II-41-27; pepstatin, pepstatin A.

Techniques: Tube Formation Assay, Irradiation, Standard Deviation, MANN-WHITNEY

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Techniques: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot, Derivative Assay

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Techniques: In Vivo, Selection, Western Blot, Expressing

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Techniques: Immunohistochemical staining, Microarray, Immunohistochemistry, Expressing

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Techniques: Western Blot, Transduction, Plasmid Preparation, Control, Mutagenesis, Comparison, Injection

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Figure Lengend Snippet: A) Analysis of log 2 transformed FPKM gene expression values extracted from bulk RNA seq published previously (Smith R. et al. Scientific Reports 2020 ) showing low Efna1-5 gene expression in commercially available castration resistant and androgen sensitive human PCa cell lines. B) Immunoblot characterization of select PCa cell lines reveals simultaneous high EphA2 expression and low EphrinA1 expression in metastatic castration resistant cells compared with androgen sensitive cells. C ) Quantitative analysis of data in (B). D) Kaplan-Meier survival curve from the MSK dataset ( Cancer Cell 2010 ). Samples were aggregated into the top 25 percent EFNA1 expressing ( EFNA1 High), and lower 75 percent EFNA1 expressing ( EFNA1 Low). Data were accessed via cBioportal.

Techniques: Transformation Assay, Expressing, RNA Sequencing Assay, Western Blot

Journal: bioRxiv

Article Title: Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment

doi: 10.1101/2024.09.25.615079

Techniques: Plasmid Preparation, Expressing, Control, Western Blot, Recombinant, In Vitro, Proliferation Assay, Imaging, Injection, Luciferase

Fig.1 The expression level of EphA2 was determined in THLE-3, HepG2 and HepG2.2.15 cell lines using immunocytochemical staining (A) (400 ×), immunofluores- cence assay (B) (400 ×) and western blotting (C). *P < 0.01 vs. THLE-3 cells, #P < 0.01 vs. HepG2 cells

Journal: Molecular biology reports

Article Title: The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma.

doi: 10.1007/s11033-022-08045-1

Figure Lengend Snippet: Fig.1 The expression level of EphA2 was determined in THLE-3, HepG2 and HepG2.2.15 cell lines using immunocytochemical staining (A) (400 ×), immunofluores- cence assay (B) (400 ×) and western blotting (C). *P < 0.01 vs. THLE-3 cells, #P < 0.01 vs. HepG2 cells

Article Snippet: Following blocking with 5% goat serum, the cells were incubated with a rabbit anti-EphA2 monoclonal antibody (1:100; CST, MA, USA) at 4 °C overnight and were immersed in a solution of horseradish peroxidase-labelled secondary antibody for at 37 °C 30 min. After stained with DAB, the cells were dehydrated, cleared and mounted.

Techniques: Expressing, Staining, Western Blot

Fig.2 The migration activity of HCC cells was determined using the scratch assay (100 ×). #P < 0.05 * P< 0.01 between HepG2 and HepG2.2.15 cells, between HepG2.2.15 and HepG2.2.15-EphA2-RNAi cells, between HepG2 and HepG2-EphA2-RNAi cells, and between HepG2-EphA2-RNAi cells and HepG2.2.15-EphA2- RNAi cells

Journal: Molecular biology reports

Article Title: The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma.

doi: 10.1007/s11033-022-08045-1

Figure Lengend Snippet: Fig.2 The migration activity of HCC cells was determined using the scratch assay (100 ×). #P < 0.05 * P< 0.01 between HepG2 and HepG2.2.15 cells, between HepG2.2.15 and HepG2.2.15-EphA2-RNAi cells, between HepG2 and HepG2-EphA2-RNAi cells, and between HepG2-EphA2-RNAi cells and HepG2.2.15-EphA2- RNAi cells

Techniques: Migration, Activity Assay, Wound Healing Assay

Fig.3 The invasion activity of HCC cells was determined using the scratch assay (100 ×). #P < 0.05 *P < 0.01 between HepG2 and HepG2.2.15 cells, between HepG2.2.15 and HepG2.2.15-EphA2-RNAi cells, between HepG2 and HepG2-EphA2-RNAi cells, and between HepG2-EphA2-RNAi cells and HepG2.2.15-EphA2- RNAi cells

Journal: Molecular biology reports

Article Title: The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma.

doi: 10.1007/s11033-022-08045-1

Figure Lengend Snippet: Fig.3 The invasion activity of HCC cells was determined using the scratch assay (100 ×). #P < 0.05 *P < 0.01 between HepG2 and HepG2.2.15 cells, between HepG2.2.15 and HepG2.2.15-EphA2-RNAi cells, between HepG2 and HepG2-EphA2-RNAi cells, and between HepG2-EphA2-RNAi cells and HepG2.2.15-EphA2- RNAi cells

Techniques: Activity Assay, Wound Healing Assay

Fig.4 The expressions of E-cadherin and Vimentin were determined in HCC cells using immunofluorescence assay (400 ×). a1P < 0.05 a2P < 0.01 between HepG2 and HepG2.2.15 cells, b1P < 0.01 b2P < 0.01 between HepG2 and HepG2-EphA2-RNAi cells, c1P < 0.01 c2P < 0.01 between HepG2.2.15 and HepG2.2.15- EphA2-RNAi cells, d1P < 0.05 d2P < 0.01 between HepG2- EphA2-RNAi cells and HepG2.2.15-EphA2-RNAi cells

Journal: Molecular biology reports

Article Title: The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma.

doi: 10.1007/s11033-022-08045-1

Figure Lengend Snippet: Fig.4 The expressions of E-cadherin and Vimentin were determined in HCC cells using immunofluorescence assay (400 ×). a1P < 0.05 a2P < 0.01 between HepG2 and HepG2.2.15 cells, b1P < 0.01 b2P < 0.01 between HepG2 and HepG2-EphA2-RNAi cells, c1P < 0.01 c2P < 0.01 between HepG2.2.15 and HepG2.2.15- EphA2-RNAi cells, d1P < 0.05 d2P < 0.01 between HepG2- EphA2-RNAi cells and HepG2.2.15-EphA2-RNAi cells

Techniques: Immunofluorescence

Fig.5 The expressions of p-GSK-3βSer9 and β-catenin were determined in HCC cells using immunofluorescence assay (400 ×). a1P < 0.01 a2P < 0.01 between HepG2 and HepG2.2.15 cells, b1P < 0.01 b2P < 0.01 between HepG2 and HepG2-EphA2-RNAi cells, c1P < 0.01 c2P < 0.01 between HepG2.2.15 and HepG2.2.15- EphA2-RNAi cells, d1P < 0.01 d2P < 0.01 between HepG2- EphA2-RNAi cells and HepG2.2.15-EphA2-RNAi cells

Journal: Molecular biology reports

Article Title: The significance of EphA2-regulated Wnt/β-catenin signal pathway in promoting the metastasis of HBV-related hepatocellular carcinoma.

doi: 10.1007/s11033-022-08045-1

Figure Lengend Snippet: Fig.5 The expressions of p-GSK-3βSer9 and β-catenin were determined in HCC cells using immunofluorescence assay (400 ×). a1P < 0.01 a2P < 0.01 between HepG2 and HepG2.2.15 cells, b1P < 0.01 b2P < 0.01 between HepG2 and HepG2-EphA2-RNAi cells, c1P < 0.01 c2P < 0.01 between HepG2.2.15 and HepG2.2.15- EphA2-RNAi cells, d1P < 0.01 d2P < 0.01 between HepG2- EphA2-RNAi cells and HepG2.2.15-EphA2-RNAi cells

Techniques: Immunofluorescence

Review

Structured Review

Images

1) Product Images from "Skeletal Metastasis of Prostate Cancer Is Augmented by Activation of EphA2 Noncanonical Signaling and Ligand-Deficient Bone Microenvironment"

Similar Products

Image Search Results